677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.

@article{Kurzawski2007677CTA1,
  title={677C>T and 1298A>C MTHFR polymorphisms affect methotrexate treatment outcome in rheumatoid arthritis.},
  author={M. Kurzawski and A. Pawlik and K. Safranow and M. Herczyńska and M. Droździk},
  journal={Pharmacogenomics},
  year={2007},
  volume={8 11},
  pages={
          1551-9
        }
}
  • M. Kurzawski, A. Pawlik, +2 authors M. Droździk
  • Published 2007
  • Medicine
  • Pharmacogenomics
  • INTRODUCTION Methotrexate (MTX), widely used in the treatment of rheumatoid arthritis (RA), inhibits dihydrofolate reductase and folate-dependent enzymes. Methylenetetrahydrofolate reductase (MTHFR) is involved in folate metabolism and has been shown to be polymorphic, affecting the enzyme activity. METHODS To examine the association between 677C>T and 1298A>C MTHFR polymorphisms and MTX efficacy in the treatment of RA, a total of 174 RA patients, treated with MTX plus methylprednisone 4 mg… CONTINUE READING

    Topics from this paper.

    Associations between the C677T and A1298C Polymorphisms of MTHFR and the Efficacy and Toxicity of Methotrexate in Rheumatoid Arthritis
    • 65
    • Highly Influenced
    • Open Access

    References

    Publications referenced by this paper.
    SHOWING 1-10 OF 43 REFERENCES
    A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase
    • 5,453
    • Open Access